Robert B Livingston

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. pmc Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    EJNMMI Res 2:34. 2012
  2. pmc SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
    Robert B Livingston
    Arizona Cancer Center, Hematology Oncology Section, Tucson, AZ, 85724 5024, USA
    Breast Cancer Res Treat 130:123-31. 2011
  3. pmc Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500
    Jeffrey B Smerage
    Jeffrey B Smerage, Anne F Schott, and Daniel F Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing Sheela Tejwani, Henry Ford Hospital, Detroit, MI William E Barlow and Danika L Lew, SWOG Statistical Center Julie R Gralow, Seattle Cancer Care Alliance, Seattle, WA Gabriel N Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX Eric P Winer, Dana Farber Cancer Institute, Boston, MA Brian Leyland Jones, Avera Cancer Institute, Sioux Falls, SD Mark A O Rourke, Greenville Health System Cancer Institute Greenville Community Clinical Oncology Program, Greenville, SC Gerald V Doyle, Immunicon, Huntingdon Valley, PA and Robert B Livingston, University of Arizona Cancer Center, Tucson, AZ
    J Clin Oncol 32:3483-9. 2014
  4. doi request reprint Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
    Leona Downey
    Arizona Cancer Center, Tucson, Arizona 85724, USA
    Clin Cancer Res 16:1281-8. 2010

Collaborators

Detail Information

Publications4

  1. pmc Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients
    Brenda F Kurland
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    EJNMMI Res 2:34. 2012
    ..abstract:..
  2. pmc SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
    Robert B Livingston
    Arizona Cancer Center, Hematology Oncology Section, Tucson, AZ, 85724 5024, USA
    Breast Cancer Res Treat 130:123-31. 2011
    ..The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC with minimal toxicity. One-year survival estimates are among the highest reported in this population...
  3. pmc Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500
    Jeffrey B Smerage
    Jeffrey B Smerage, Anne F Schott, and Daniel F Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing Sheela Tejwani, Henry Ford Hospital, Detroit, MI William E Barlow and Danika L Lew, SWOG Statistical Center Julie R Gralow, Seattle Cancer Care Alliance, Seattle, WA Gabriel N Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX Eric P Winer, Dana Farber Cancer Institute, Boston, MA Brian Leyland Jones, Avera Cancer Institute, Sioux Falls, SD Mark A O Rourke, Greenville Health System Cancer Institute Greenville Community Clinical Oncology Program, Greenville, SC Gerald V Doyle, Immunicon, Huntingdon Valley, PA and Robert B Livingston, University of Arizona Cancer Center, Tucson, AZ
    J Clin Oncol 32:3483-9. 2014
    ..A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival (OS)...
  4. doi request reprint Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
    Leona Downey
    Arizona Cancer Center, Tucson, Arizona 85724, USA
    Clin Cancer Res 16:1281-8. 2010
    ..This hypothesis was examined using the data from a phase III trial that randomized patients with HER2-negative or HER2-untested metastatic breast cancer to first-line therapy with paclitaxel along with either lapatinib or placebo...